July 2, 2024

The Summer 2024 advocacy blog, Considering Clinical Trials, is now available

June 14, 2024

E1910 trial leads to an FDA approval in B-cell acute lymphoblastic leukemia (B-ALL)

November 15, 2023

Press Release: ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

October 19, 2023

The September/October 2023 News from ECOG-ACRIN blog is now available

July 19, 2023

The Summer 2023 advocacy blog, Considering Clinical Trials, is now available

February 15, 2023

A participant in the E1910 trial shares her experience in a Penn Medicine feature story with her hematologist, Dr. Selina Luger

December 20, 2022

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

December 15, 2022

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

ECOG-ACRIN Cancer Research Group